Abatacept

This page contains recent news articles, when available, and an overview of Abatacept but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Maxygen Buying Back Stock; Analysts Say No Trend Here  -  14 Nov 2009
...s rheumatoid arthritis drug Orencia (abatacept), in a back-end loaded $170 million deal with Astellas Pharma Inc. The companies later expanded the deal into ... BioWorld Online

New Data Describe Safety of Subcutaneous Administration of ORENCIA® (abatacept ...  -  ‎Oct 20, 2009‎
Acute injection site reactions were reported in 7 patients (3 patients in the ORENCIA® (abatacept) plus methotrexate cohort and 4 patients in the ORENCIA ... Reuters

ORENCIA® (abatacept) Demonstrated Sustained Clinical Response in a Study of ...  -  ‎Oct 19, 2009‎
The US Food and Drug Administration approved on August 25, 2009, an update in the labeling for ORENCIA® (abatacept) to include data from the AGREE trial ... Reuters

ACR: Abatacept Efficacy in RA Lasts for Two Years  -  ‎Oct 23, 2009‎
Explain that abatacept is approved for moderate to severe rheumatoid arthritis. Note that these studies were published as abstracts and presented at a ... MedPage Today

Judgement In Favour Of NICE On Judicial Review Of Abatacept For Rheumatoid ...  -  ‎Nov 10, 2009‎
The High Court has ruled in favour of NICE by dismissing the application from Bristol Myers Squibb (BMS), the manufacturer of abatacept, for a judicial ... Medical News Today (press release)

Bristol-Myers Squibb's Orencia Shows Sustained Clinical Response In Two-year ...  -  ‎Oct 19, 2009‎
...(BMY: News ) said data from a two-year study on its drug Orencia or abatacept, showed low disease activity, among other improvements, in patients with ... RTT News

Cochrane review finds abatacept effective  -  ‎Nov 1, 2009‎
There is "moderate-level" evidence that the immunomodulator abatacept is safe and effective but it should not be given with other biologics, ... Rheumatology Update

Bristol-Myers Squibb Releases Study Results that Support Orencia  -  ‎Oct 22, 2009‎
The US Food and Drug Administration approved on August 25, an update in the labeling for Orencia (abatacept) to include data from the Agree trial (Abatacept ... Trading Markets (press release)

Alder and New Partner, Bristol, to Give Amgen and Abbott a Run for Their Money  -  ‎Nov 10, 2009‎
Alder ultimately chose Bristol-Myers (NYSE: BMY) because it has experience in the rheumatoid arthritis field through its FDA-approved abatacept (Orencia) ... Xconomy

High Court rejects B-MS bid for NICE legal challenge  -  ‎Nov 10, 2009‎
The cost watchdog ruled back in April last year that Orencia (abatacept) was simply too expensive for use on the NHS to treat patients with moderate-severe ... Pharma Times

HGSI's Phase III Benlysta Details Boost Confidence in Second Trial  -  ‎Oct 20, 2009‎
Bristol-Myers Squibb Co., of New York, presented data from an open-label study of rheumatoid arthritis drug Orencia (abatacept) showing minimal ... BioWorld Online

Where are data on effectiveness of 'Aminomics'?  -  ‎Nov 1, 2009‎
...that the novel "biologic" drug abatacept is effective against rheumatoid arthritis and that migraine patients can benefit from acupuncture. ... The Gazette (Montreal)

ACR70-disease activity score remission achievement from switches between all ...  -  ‎Nov 3, 2009‎
Clinical trials confirmed the efficacy in switching to abatacept (gain of effect 10.2%). Tocilizumab allows to reach DAS28 remission in 30.1% but ACR70 only ... 7thSpace Interactive (press release)

New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and ...  -  ‎Oct 26, 2009‎
An increased risk of serious infections has been seen in clinical trials of other TNF blocking agents used in combination with anakinra or abatacept. ... Reuters

New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With ...  -  ‎Oct 19, 2009‎
...tired Tell your doctor about all the medications you take including ORENCIA (abatacept), KINERET (anakinra), RITUXAN (rituximab) or another TNF blocker, ... Reuters

B-MS posts strong sales for most of its drugs  -  ‎Oct 23, 2009‎
As for B-MS' newer drugs, Sprycel (dasatanib) for leukaemia rose 30% to $107 million, while Orencia (abatacept) for rheumatoid arthritis increased 36% to ... Pharma Times

국내 �?�료진 류마티스치료제 기전 규명  -  ‎Oct 30, 2009‎
...서울성모병�? 류마티스센터 김호연 �?수팀�?� 류마티스관절염 치료�? �?리 사용�?�고 있는 면역조절약물 'CTLA4-Ig (Abatacept)'�?� �?가면역반�?��?� 억제하는 면역조절 T ... 파이낸셜뉴스

BMS, 관절염 치료항체 �?�입  -  ‎Nov 10, 2009‎
...�?�는 류마티스성 관절염�? 대해 2a�? 임�?�?� 마친 제제로서, BMS는 ALD518�? 대해 '오렌시아'(Orencia, abatacept) 등 기존 치료제보다�?� 효과와 안전성�?� 뛰어날 ... 디지틀보사

Bristol-Myers�?�表风湿性关节炎实验  -  ‎Oct 20, 2009‎
...(BMY) 22.97 : BrIStol-Myers宣布最新临床数�?�，支�?继续开�?�皮下注射剂ORENCIA (abatacept)，治疗中度与严�?风湿性关节炎病患。本研究显示，�?周注射一次125 mg ... 凤凰网

Bristol-Myers發表風濕性關節炎實驗  -  ‎Oct 20, 2009‎
...(BMY: 報價) 22.97 : Bristol-Myers宣佈最新臨床數據，支�?繼續開發皮下注射劑ORENCIA (abatacept)，治療中度與嚴�?風濕性關節炎病患。本研究顯示，�?週注射一次125 ... 環球財經

Bristol-Myers Squibb's Orencia Gets Wider Labeling Approval From FDA  -  ‎Aug 26, 2009‎
The broader labeling approval was based on clinical data from the Abatacept study that showed Orencia helped patients with moderate-to-severe rheumatoid RTT News

Health and medical news from abc12.com  -  ‎Aug 28, 2009‎
He gets monthly infusions of a rheumatoid arthritis drug called abatacept. The goal is to stop Daniel's immune system from killing the insulin-producing ABC12.com

BiomedReports: News and FDA Updates for Bristol-Myers (NYSE:BMY ...  -  ‎Aug 27, 2009‎
On 08/26/09, Bristol-Myers Squibb Company (NYSE:BMY), announced clinical data added to the labeling for ORENCIA (abatacept) support use of ORENCIA for Trading Markets (press release)

GDH-PQQ Glucose Test Strips May Produce Falsely Elevated Results  -  ‎Aug 14, 2009‎
Interfering products containing nonglucose sugars include icodextrin peritoneal dialysis solution, certain immunoglobulins, abatacept (Orencia, Medscape

Immunology's quiet upheaval  -  ‎Aug 21, 2009‎
Similarly, the co-stimulatory blocking agent Orencia (abatacept; Bristol-Myers Squibb, Princeton, New Jersey) may work in rheumatoid arthritis by blocking a Nature.com (subscription)

Financings of the Fortnight: Follow-On Fever  -  ‎Aug 13, 2009‎
Bristol's Orencia (abatacept) is in Phase III trials for lupus, a disease that hasn't seen a new therapy in generations; a companion diagnostic could give The IN VIVO Blog

UCB and its design partners, OXO® and Smart Design, win 2009 "Red ...  -  ‎Aug 11, 2009‎
The use of Cimzia® in combination with biological DMARDS such as anakinra, abatacept and rituximab is not recommended due to a potential increased risk of PR-Inside.com (Pressemitteilung)

'오렌시아' �?�?��?�? '관절염치료 효과' 추가 표시  -  ‎Aug 28, 2009‎
...김윤�? 기�? BMS는 FDA가 최근 �?사 류마티스 관절염(RA) 치료제 오렌시아(Orencia: abatacept)�? 대해 설명서�?� 표시변경�?� 허가한 사실�? 고무�?�어 �?매 촉진�? 전력 메디포뉴스

FDA, BMS '오렌시아' �?�?� 범위 확대 승�?�  -  ‎Aug 26, 2009‎
BMS는 류마티스 관절염 치료제 '오렌시아(Orencia, abatacept)'�? 대한 �?�?��? 확대 조치가 �?�뤄졌다고 26�?� �?혔다. FDA는 연구결과 오렌시아가 2년 미만 �?�안 데일리팜

Caracas será la sede del V Simposio Internacional de Reumatología 2009  -  13 Jul 2009
...y el Dr. Oscar Jair Felipe con una exposición sobre “Uso de Abatacept en Artritis Reumatoide/Diferentes Escenarios�?; en estas presentaciones se El Observador (Venezuela)

EULAR: Abatacept Efficacy in Juvenile Arthritis Lasts Beyond Two Years  -  ‎Jun 17, 2009‎
COPENHAGEN, June 17 -- Children with juvenile idiopathic arthritis continued to respond to abatacept (Orencia) MedPage Today

EULAR: Analysis Slams Infliximab in Early RA  -  ‎Jun 17, 2009‎
Explain that the manufacturer of abatacept funded the analysis and several of its employees helped conduct it. Note that this study was published as an MedPage Today

New Rheumatoid Arthritis Drug Shows Promising Results  -  ‎Jul 1, 2009‎
...“For those patients who have failed or had an inadequate response to etanercept, infliximab, adalimumab, or abatacept, golimumab might be a good option,�? he HealthNews

Patients to benefit on some segments  -  ‎Jul 7, 2009‎
Tocilizumab, a monoclonal antibody used in rheumatology; Pegaptanib Sodium injection, used in age-related eye problems and Abatacept, a fusion protein. istockAnalyst.com (press release)

Golimumab Treats RA When Other TNF-Alpha Inhibitors Fail  -  ‎Jun 29, 2009‎
...agent the FDA has approved for rheumatoid arthritis, joining etanercept (Enbrel), infliximab (Remicade), adalimumab (Humira), and abatacept (Orencia). MedPage Today

SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for ...  -  ‎Jun 26, 2009‎
The concurrent administration of TNF-antagonists with anakinra or abatacept is not recommended. Concurrent administration has been associated with increased PR Newswire (press release)

Bristol-Myers Squibb change distribution arrangements  -  ‎Jun 24, 2009‎
These products are aztreonam, etoposide phosphate, abatacept, atazanavir, dasatanib, efavirenz, etoposide, didanosine, and stavudine. Dispensing Doctors' Association

Farmaci: Abatacept per l'artrite reumatoide  -  ‎Jun 17, 2009‎
Dopo 7 anni di terapie i pazienti che sono stati trattati con Abatacept, parte dei quali ancora in terapia, hanno dimostrato che nella metà dei casi si sono NanoPress

�?ртрит атакува и децата  -  ‎Jul 8, 2009‎
В момента �?ъще�?твуват пет вида - etanercept, infliximab, adalimumab, abatacept и anakinra. Три от т�?х блокират дей�?твието на тумор некрози�? фактора. Стандарт

El uso inicial de HUMIRA ® más metotrexato puede prevenir nuevo ...  -  ‎Jul 8, 2009‎
No se recomienda la combinación de HUMIRA y anakinra o de HUMIRA y abatacept. Los acontecimientos adversos con una relación al menos posiblemente causal con Ibáñez & Plaza (Comunicado de prensa)

Arthritis Biologics  -  20 Apr 2009
...adalimumab (HUMIRA®), infliximab (Remicade®), rituximab (Rituxan®), anakinra (Kineret®) and abatacept (ORENCIA®). According to the Arthritis Foundation, WTVQ

BioWorld Today April 16, 2009  -  ‎Apr 15, 2009‎
...including tumor necrosis factor-alpha inhibitors like Enbrel (etanercept, Amgen Inc.) and anti-inflammatory antibodies like Orencia (abatacept, Therapeutics Daily (press release) (registration)

[중견기업�?�커스]코스닥 대장주 비결�?� ‘역발�? 전략’  -  ‎Mar 30, 2009‎
...�?�후 바�?�오 �?�약품 �?산 기술�?� 합법�?으로 �?�전받�?� 서 회장�?� 2005년 미국�?� 다국�? 제약사�?� BMS와 류마티스 관절염 치료제�?� 아바타셉트(Abatacept) 장기 공급 헤럴드경제

VICTIMS OF SOCIALISM  -  ‎Mar 9, 2009‎
...patients' lives, and Abatacept, even though it's one of the only drugs that has been shown in clinical testing to improve severe rheumatoid arthritis. National Center for Policy Analysis

Young Diabetes Patient Hopes To Help Others By Testing Arthritis Drug  -  Jan 21, 2009
It's part of the national Type 1 Diabetes TrialNet series of studies, this one testing an arthritis drug called Abatacept to see if it can stop a rogue WAAY,

XDx Inks PGx Collaboration with Bristol-Myers for Lupus  -  Jan 9, 2009
The firms will be working on tests to monitor the effectiveness of Bristol-Myers’ rheumatoid arthritis drug abatacept (Orencia) in treating lupus. GenomeWeb News,

Korean fine chems work in the shadows  -  Feb 3, 2009
Customers include Bristol-Myers Squibb, which awarded Celltrion a long-term supply contract for Orencia (abatacept), a treatment for rheumatoid arthritis. ICIS (subscription),

Roche: RoActemra gets EU green light  -  Jan 22, 2009
RoActemra will also compete with Bristol-Myers Squibb's Orencia (abatacept), which has a well-perceived safety profile. RoActemra nevertheless has great Pharmaceutical Business Review

B-MS doing so well that analysts expect takeover approaches  -  Jan 28, 2009
Sprycel (dasatanib) for leukaemia rose 54% to $86 million, while Orencia (abatacept) for rheumatoid arthritis increased 72% to $129 million. Pharma Times,

What treatments work for rheumatoid arthritis?  -  Jan 21, 2009
Abatacept: This drug is sometimes used to treat people who haven't been helped by other treatments. Its brand name is Orencia. It slows the damage to your guardian.co.uk,

Earnings Preview : Bristol Myers Squibb (NYSE:BMY)  -  Jan 25, 2009
...associated with the clinical development of Orencia® (abatacept), a Bristol-Myers Squibb drug approved for the treatment of rheumatoid arthritis. istockAnalyst.com (press release),

Sanofi may bid for Crucell; FDA opens Costa Rica office;  -  Jan 9, 2009
The collaboration is focused on identifying biomarkers for clinical diagnostic purposes associated with the clinical development of Orencia (abatacept), FierceBiotech,

Other News To Note  -  Jan 9, 2009
...biomarkers in the field of systemic lupus erythematosus for clinical diagnostic purposes associated with development of BMS' Orencia (abatacept). TMCnet

Government price controls can't fix health care  -  Jan 12, 2009
Just look at what happened last year when NICE decided that the arthritis drug abatacept was too costly to cover. Despite the fact that the drug is one of Washington Examiner,

Asian contractors aim for growth in biologics  -  Jan 19, 2009
...major Bristol-Myers Squibb was just then scouring the globe to find additional capacity for a blockbuster monoclonal antibody, Orencia (abatacept). ICIS (subscription),

XDx, Bristol-Myers in collaboration Silicon Valley / San Jose ...  -  Jan 9, 2009
...associated with the clinical development of Orencia (abatacept), a Bristol-Myers Squibb drug approved for the treatment of rheumatoid arthritis. Bizjournals.com,

Vaccini anti malaria e pneumococco  -  Jan 15, 2009
Stanno per essere registrati e immessi sul mercato due farmaci biologici, adalimubab e abatacept, per la cura dell'artrite idiopatica giovanile. La Repubblica,

I nuovi farmaci biotecnologici  -  Jan 15, 2009
Recentemente sono stati approvati nel nostro Paese inibitori dei linfociti T, come il rituximab (Mabthera), o dei linfociti B, come l'abatacept (Orencia). La Repubblica,

BMS 분�?진단사와 ‘오렌시아’ 제휴  -  Jan 13, 2009
...브리스톨-마�?�어스스퀴브(BMS)는 분�?진단 회사�?� XDx와 류마티스 관절염 치료제�?� '오렌시아'(Orencia, abatacept) 관련 약물유전체학 제휴를 체결했다. 디지틀보사,

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.